The Pharmacy and Poisons Board (PPB) has issued a critical public health warning against the dangerous, unsupervised use of diabetes drug semaglutide containing drugs popularly sold under the brand name Ozempic for weight loss.
Dr. Fred Siyoi, CEO of the Pharmacy and Poisons Board (PPB) warned members of the public that semaglutide is strictly for prescription only use in the management of type 2 diabetes, and its misuse can lead to severe and life-threatening complications.
He said that while semaglutide has shown proven efficacy for diabetic patients, “PPB has observed a concerning rise in its off-label use for cosmetic weight loss, fueled by social media trends and unauthorized sales. This practice bypasses crucial medical oversight, putting individuals at significant risk.”
Semaglutide is a powerful medicine, not a quick-fix weight-loss tool,Dr Siyoi said, adding that, “Without a doctor’s supervision, users are exposed to a range of serious side effects that can escalate quickly, from debilitating acid reflux and intestinal blockages to dangerous hypoglycemia and vision-threatening eye complications.”
The PPB warns Kenyans to be vigilant and avoid self-prescribing or purchasing semaglutide from unverified online sources or individuals.
The Board’s mandate is to ensure the safety, efficacy, and quality of all Health Products and Technologies (HPTs) in the country, and the unauthorized distribution of these drugs undermines public safety.
The public is urged to report any adverse reactions, suspected counterfeit products, or illegal sales of semaglutide immediately. Reports can be made through the Pharmacovigilance Electronic Reporting System at pv.pharmacyboardkenya.org, via email at pv@ppb.go.ke, by phone on +254 795 743 049, or through the USSD code *271#.
“The PPB remains committed to working with healthcare professionals and the public to promote the safe and rational use of medicines, ensuring that powerful treatments are used for their intended purpose under expert guidance,” Dr Siyoi said.
